Is it time to do a 360 degree u-turn and buy this penny stock?

There’s a penny stock that’s recently grabbed the headlines for the right reasons. Is it time for me to think again and buy some of the shares?

| More on:
Young female business analyst looking at a graph chart while working from home

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With a stock market valuation of less than £100m and a share price below £1, Angle (LSE:AGL) meets the definition of a penny stock.

The last time I wrote about the company I said that taking a position would be based on “a hunch” rather than a proper understanding of what the company does and its prospects.

It describes itself as a “world-leading liquid biopsy company with innovating circulating tumour cell solutions”. Its technical reports make for heavy reading and, to be honest, I don’t really understand them, which is why I said I didn’t want to buy any of its stock.

That was on 19 January. Since then, the share price has risen 12%. However, despite this good run, they are 70% lower than they were in May 2019.


But is my approach justified, or am I being a hypocrite?

For example, I own shares in Lloyds Bank. And yet I can’t say with my hand on my heart that I fully understand how financial institutions work and the industry in which they operate.

Yes, I know what a bank does and how it makes money. But when it comes to the intricacies of the sector, I haven’t a clue. I don’t know what CRD IV models are. Nor do I understand countercyclical capital buffers. As for Pillar 2A requirements …

So my reasons for not investing in Angle are probably misplaced.

I’m aware that the company is trialling a cancer diagnostics tool. In January, it announced that initial results show that in 70% of patients, its technology found cancer mutations in cells that could not be identified from the DNA in the same blood.

And the more successful it is at detecting cancer — and the more lives it saves — the more money it will make.

Simple. And worthy.

The key question

But should I invest?

Well, in April, the company signed an agreement with AstraZeneca to develop a novel approach to tumour detection. It’s worth a relatively modest £150k. But the company must be good at what it does if the UK’s most valuable listed company wants to partner with it.

This was followed up, in May, by another agreement with AstraZeneca worth £550k. The two parties are looking at ways of identifying prostate cancer at an earlier stage.

If successful, these projects could lead to further collaborations or, perhaps, a takeover.

There’s little point dwelling on the company’s financial history. At 30 June 2023, it had accumulated losses of £113m. Revenue for 2023 is expected to be £2.2m. This company is all about the future.

Encouragingly, it claims to have enough cash to see it through until, at least, early 2025. Although with a market cap of £55m, it doesn’t have the financial might to withstand a shock to its business.

And there are no guarantees when it comes to medical research. It’s hugely expensive and failure is common. However, if successful, the rewards are large.

But despite these risks, I’m going to put the company on my watchlist for when I next invest. It looks like a company that’s going places.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Beard has positions in Lloyds Banking Group Plc. The Motley Fool UK has recommended AstraZeneca Plc and Lloyds Banking Group Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

These are the most popular 2024 Stocks and Shares ISA picks so far

After a few tough years, it looks like the 2024 Stocks and Shares ISA season is getting off to a…

Read more »

Investing Articles

This FTSE 100 ETF may be the simplest way to become a stock market millionaire

Ben McPoland considers one very straightforward stock market investing strategy that could lead to a million-pound portfolio.

Read more »

Investing Articles

I’d buy 11,220 Legal & General shares for £200 a month in passive income

Our writer considers how much money investors would have to put into Legal & General (LON:LGEN) shares to target £2,400…

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

These 2 magnificent FTSE 250 shares are on sale right now!

These FTSE 250 companies still look cheap, despite recent share price gains. Here's why our writer Royston Wild thinks they’re…

Read more »

Blue NIO sports car in Oslo showroom
Growth Shares

Down 36% in 2024, how low could NIO shares go?

The electric vehicle sector has seen some tremendous volatility in recent years, but what does the future hold for NIO…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

£5,000 in savings? Here is how I would invest in income shares

This Fool has been searching for ways to generate a passive return via income shares.

Read more »

Market Movers

The Keywords Studios share price just jumped 63%. Time to sell?

The Keywords Studios share price has soared on the back of takeover talk. Here, Edward Sheldon explains what he’d do…

Read more »

ESG concept of environmental, social and governance.
Investing Articles

5 sustainable UK stocks that Fools love

Five completely different stocks, all listed in the UK, that tick a wealth of ESG boxes as well as looking…

Read more »